RenovoRx (RNXT) Fundamentals 2026 — Revenue Analysis | SniperIQ
RenovoRx (RNXT) is a US-listed Healthcare company in Biotechnology with a market capitalization of
RenovoRx's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
RenovoRx runs a net profit margin of -824.0%, a gross margin of 78.7%, and an operating margin of -864.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
RenovoRx reported revenue of